This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wire, M. B. Articles by Berrey, M. M. Search for Related Content PubMed PubMed Citation Articles by Wire, M. B. Articles by Berrey, M. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2006, p. 1578-1580, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1578-1580.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV

Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, North Carolina,¹ Clinical Pharmacology Data Science, GlaxoSmithKline, Research Triangle Park, North Carolina,² Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Philadelphia, Pennsylvania³

Received 15 September 2005/ Returned for modification 30 October 2005/ Accepted 16 January 2006

To compare the effect of ritonavir on plasma amprenavir pharmacokinetics, healthy adults received either fosamprenavir (700 mg twice a day [BID]) or amprenavir (600 mg BID) alone and in combination with ritonavir (100 mg BID). Ritonavir increased plasma amprenavir pharmacokinetic parameters to a similar extent when coadministered with either fosamprenavir or amprenavir.

This article has been cited by other articles:

• Ford, S. L., Chen, Y.-C., Lou, Y., Borland, J., Min, S. S., Yuen, G. J., Shelton, M. J. (2008). Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Antimicrob. Agents Chemother. 52: 534-538 [Abstract] [Full Text]  
• Okusanya, O., Forrest, A., DiFrancesco, R., Bilic, S., Rosenkranz, S., Para, M. F., Adams, E., Yarasheski, K. E., Reichman, R. C., Morse, G. D., and the ACTG 5043 Protocol Team, (2007). Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks. Antimicrob. Agents Chemother. 51: 1822-1826 [Abstract] [Full Text]  
• Pellegrin, I., Breilh, D., Coureau, G., Boucher, S., Neau, D., Merel, P., Lacoste, D., Fleury, H., Saux, M.-C., Pellegrin, J.-L., Lazaro, E., Dabis, F., Thiebaut, R., for the ANRS Co3 Aquitaine Cohort, (2007). Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients. Antimicrob. Agents Chemother. 51: 1473-1480 [Abstract] [Full Text]  
• DeJesus, E., Piliero, P. J., Summers, K., Wire, M. B., Stein, D. S., Masterman, A., Lou, Y., Min, S. S., Shelton, M. J. (2006). Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects.. Antimicrob. Agents Chemother. 50: 3157-3159 [Abstract] [Full Text]